In a report released today, Anupam Rama from J.P. Morgan maintained a Hold rating on Kodiak Sciences (KOD – Research Report), with a price target of $10.00. The company’s shares closed yesterday at $5.44.
According to TipRanks, Rama is an analyst with an average return of -0.4% and a 44.10% success rate. Rama covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, BridgeBio Pharma, and Neurocrine.
The word on The Street in general, suggests a Hold analyst consensus rating for Kodiak Sciences with a $9.67 average price target.
See today’s best-performing stocks on TipRanks >>
KOD market cap is currently $284.4M and has a P/E ratio of -0.85.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Read More on KOD:
